Werkgroep Cardiologische centra Nederland

HF-REVERT (Follow-up)

Phase 2, Multicentre, Randomised, Double-blind, Parallel, 3-arm, Placebo-controlled Study to Assess Efficacy and Safety of CDR132L in Patients With Reduced Left Ventricular Ejection Fraction (≤45%) After Myocardial Infarction
Medicine
CDR132L
Population
ASCVD
Phase
II
Starting year
2021

Director of Study

dr. T. Oosterhof (Cardioloog)
Ede, Gelderse Vallei Ziekenhuis